Skip to content
Disclosery

venBio Partners LLC

Follow

13F filer, CIK 1776382, SAN FRANCISCO, CA

venBio Partners LLC reported $280,553,201 across 6 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000905148-26-002409

Period
2026-03-31
Reported value
$281M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ALXOadded+3,184,713$6.39M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ALMSreduced-91,395-$2.01M
ARTVreduced-117,170-$755K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0000905148-26-002409, largest first. % of portfolio is the value over $280,553,201, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,289,304 shares; 2024Q4: 4,289,304 shares; 2025Q1: 4,289,304 shares; 2025Q2: 4,289,304 shares; 2025Q3: 4,639,304 shares; 2025Q4: 4,639,304 shares; 2026Q1: 4,639,304 shares 4,639,304$131M46.71%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,826,048 shares; 2024Q4: 2,787,398 shares; 2025Q1: 2,787,398 shares; 2025Q2: 4,619,803 shares; 2025Q3: 4,619,803 shares; 2025Q4: 4,619,803 shares; 2026Q1: 4,528,408 shares 4,528,408$99.8M35.56%-91,395Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 9,699,925 shares; 2024Q4: 9,699,925 shares; 2025Q1: 9,699,925 shares; 2025Q2: 9,699,925 shares; 2025Q3: 9,699,925 shares; 2025Q4: 9,699,925 shares; 2026Q1: 12,884,638 shares 12,884,638$25.8M9.21%+3,184,713Timeline
HRMYHARMONY BIOSCIENCES HLDGS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 614,594 shares; 2024Q4: 539,194 shares; 2025Q1: 489,194 shares; 2025Q2: 489,194 shares; 2025Q3: 489,194 shares; 2025Q4: 489,194 shares; 2026Q1: 489,194 shares 489,194$13.7M4.88%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 473,479 shares; 2025Q3: 473,479 shares; 2025Q4: 337,697 shares; 2026Q1: 337,697 shares 337,697$6.77M2.41%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,519,971 shares; 2024Q4: 1,519,971 shares; 2025Q1: 1,198,975 shares; 2025Q2: 1,148,975 shares; 2025Q3: 1,148,975 shares; 2025Q4: 648,507 shares; 2026Q1: 531,337 shares 531,337$3.42M1.22%-117,170Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000905148-26-002409 base2026-05-15acceptance time not in the bulk data set